Log Out

Clinical trial endpoints: Translating clinical data into real life 

Although randomised, controlled trials (RCTs) are the gold standard for assessing the efficacy and safety of a new drug, these trials are conducted in ideal conditions in restricted populations.1 This disparity between the idealised environment of an RCT and the ‘real-world’ experience of the patient is exacerbated by the complexity of MS.2 Real-world evidence can bridge that gap by revealing data on adherence, suboptimal efficacy, long-term adverse events, etc2.

In RCTs, the emphasis is on meaningful results at a population level rather than individual l